ONC
BeOne Medicines Ltd.
NASDAQ · USHealthcareMedical - Pharmaceuticals
$310.57-0.46%
Price as of Jul 20, 2026
ONC financials
BeOne Medicines Ltd. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $5.3B | $3.8B | $2.5B | $1.4B |
| Cost of revenue | $668.5M | $594.1M | $379.9M | $286.5M |
| Gross profit | $4.7B | $3.2B | $2.1B | $1.1B |
| Operating expenses | $4.2B | $3.8B | $3.3B | $2.9B |
| Operating income | $447.1M | -$568.2M | -$1.2B | -$1.8B |
| Net income | $286.9M | -$644.8M | -$881.7M | -$2.0B |
| EBITDA | $616.8M | -$361.2M | -$738.2M | -$1.9B |
| Basic EPS | $33.80 | $-6.12 | $-8.45 | $-19.37 |
| Diluted EPS | $32.11 | $-6.12 | $-8.45 | $-19.37 |
| Balance sheet | ||||
| Cash & equivalents | $4.5B | $2.6B | $3.2B | $3.9B |
| Total assets | $8.2B | $5.9B | $5.8B | $6.4B |
| Total liabilities | $3.8B | $2.6B | $2.3B | $2.0B |
| Stockholders’ equity | $4.4B | $3.3B | $3.5B | $4.4B |
| Total debt | $2.0B | $1.1B | $930.2M | $596.7M |
| Net debt | -$2.5B | -$1.5B | -$2.2B | -$3.3B |
| Cash flow | ||||
| Operating cash flow | $1.1B | -$140.6M | -$1.2B | -$1.5B |
| Capital expenditure | -$185.8M | -$529.1M | -$596.3M | -$469.1M |
| Free cash flow | $941.7M | -$669.8M | -$1.8B | -$2.0B |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |